Long-acting injectable (LAI) modalities have been developed for ART and PrEP. Women face unique barriers to LAI use yet little research has examined women’s perceptions of potential LAI HIV therapy candidates.
After 24 weeks of follow-up, switching to long-acting treatment with or without an oral lead-in phasehad similar safety, tolerability, and efficacy, supporting future evaluation of the simpler direct-to-injection approach. The week 124 results for participants randomly assigned originally to the long-acting therapy show long-acting cabotegravir plus rilpivirine remains a durable maintenance therapy with a favourable
Long-acting injectable (LAI) modalities have been developed for ART and PrEP. Women face unique barriers to LAI use yet little research has examined women’s perceptions of potential LAI HIV therapy candidates.
Cabotegravir and rilpivirine injections Read More »
Cabenuva is the first FDA-approved long-acting (LA) injectable regimen for patients with HIV infection.1 Cabenuva (ViiV Healthcare) consists of cabotegravir (CAB), an integrase strand transfer inhibitor (INSTI), and rilpivirine (RPV), a non-nucleoside reverse transcriptase inhibitor (NNRTI) approved to replace antiretroviral therapy (ART) in patients with HIV-RNA less than 50 copies/mL who have been on a
Cabenuva: A Novel Long-Acting Injectable HIV Treatment Read More »
This study presents patient-reported outcomes (PROs) collected in an HIV-1 clinical trial (ATLAS-2M; NCT03299049) comparing participants’ experience with two dosing regimens of CAB + RPV LA.
This is a summary of the 96-week results of the randomised, open-label, phase 3 FLAIR study
The objective of this study was to compare the week 48 antiviral efficacy of cabotegravir plus rilpivirine long-acting dosed every 8 weeks with that of every 4 weeks dosing.
This is a phase 3, randomized, open-label trial in which adults with HIV-1 infection who had not previously received antiretroviral therapy were given 20 weeks of daily oral induction therapy with dolutegravir-abacavir-lamivudine.
Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection. Read More »
This is a phase 3, open-label, multicenter, noninferiority trial involving patients who had had plasma HIV-1 RNA levels of less than 50 copies per milliliter for at least 6 months while taking standard oral antiretroviral therapy. The primary end point was the percentage of participants with an HIV-1 RNA level of 50 copies per milliliter
Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression. Read More »
This study evaluates the clinical evidence to date and efficacy and challenges of cabotegravir/rilpivirine long-acting, injectable in the treatment of HIV infection in selected populations.
